Other Documentation
|
|
FAQ's
|
-
Non-small cell lung cancer (NSCLC) model cell line
Date Updated: 10/12/2017
-
CRISPR/Cas9 gene editing technology
Date Updated: 10/12/2017
-
Culture conditions for A-549 VIM RFP cells
Date Updated: 10/12/2017
-
Validation of VIM RFP expression
Date Updated: 10/12/2017
|
Restrictions |
For commercial accounts, this cell line is only distributed under the terms of a fully signed and executed ATCC® Material Transfer Agreement and Addendum. If the commercial account is screening per completed Addendum, the recipient will be required to pay a Screening Fee (ATCC® ACS-2103F™).
Screening Use is defined as use of Biological Material in small molecule and biologic drug discovery, including initial target identification and validation, assay development, high throughput screening, hit identification, lead optimization, and selection of candidates for clinical development.
If the commercial account is not screening per the completed Addendum, the recipient will not be required to pay a Screening Fee.
In addition to the foregoing, this product's use is governed by the CRISPR Label License Agreement. For information on purchasing a license to use this product for purposes other than those permitted in the CRISPR Label License Agreement, please contact The Broad Institute at partnering@broadinstitute.org. This material is subject to the following restrictions in addition to those outlined in the ATCC Material Transfer Agreement:
- CRISPR Label License, ERS Genomics
For information on obtaining additional rights, please contact:
ATCC Licensing
Email: licensing@atcc.org
|
References
|
Wang W, et al Live-cell imaging and analysis reveal cell phenotypic transition dynamics inherently missing in snapshot data. Sci Adv 6(36): eaba9319, 2020. PubMed: 32917609
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2): 131-142, 2006. PubMed: 16493418
Richardson F, et al. The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res 32(2): 537-552, 2012. PubMed: 22287743
Gilles C, et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 112 (Pt 24): 4615-4625, 1999. PubMed: 10574710
|